Citigroup Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its price target raised by investment analysts at Citigroup from $135.00 to $140.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 16.02% from the stock’s current price.

Several other analysts have also issued reports on GILD. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. TD Cowen upped their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.20.

Gilead Sciences Price Performance

NASDAQ GILD opened at $120.67 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $149.71 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. The company has a 50 day simple moving average of $123.24 and a 200-day simple moving average of $117.41. Gilead Sciences has a 52-week low of $88.57 and a 52-week high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business earned $2.02 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares in the company, valued at $5,365,596.60. This trade represents a 55.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer directly owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. This represents a 1.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 136,257 shares of company stock valued at $16,855,192. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors have recently made changes to their positions in GILD. Trivium Point Advisory LLC grew its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after buying an additional 83 shares during the last quarter. Binnacle Investments Inc grew its stake in shares of Gilead Sciences by 11.8% in the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC grew its stake in shares of Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares during the last quarter. Hemington Wealth Management increased its position in Gilead Sciences by 9.3% during the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 85 shares during the period. Finally, Ignite Planners LLC raised its stake in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.